Simplyali241

VIMTA Labs LONG after multiyear breakout

Pembelian
NSE:VIMTALABS   VIMTA LABORATORIES
Vimta Labs is engaged in the business of testing food and drugs. It also does contract research for clinical research and pre-clinical studies.
Company was expected to give good quarter and has delivered.

VIMTA LABS: Q2 CONS NET PROFIT 97M RUPEES VS 75M (YOY); 81M (QOQ) || Q2 REVENUE 754M RUPEES VS 593M (YOY); 613M (QOQ)
DII have bought significantly in the last quarter, Some news is coming up
TARGET : See CHART

Pernyataan Penyangkalan

Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.